Mar. 20 at 8:09 AM
$TNON If revenue in Q4/25 were to exceed
$1.7 million, although 1.5 Mi is good, investors would be euphoric, especially given the pending FDA submission.
Since the process of expanding already commercialized products is lengthy, the commitment of the well-paid management team to this expansion will be closely watched.
Very high potential in the medium to long term.
